Apellis’ Geographic Atrophy Treatment Rejected Again by EMA
The European Medicines Agency (EMA) confirmed its decision to refuse market authorization for Apellis Pharmaceuticals’ (Waltham, Massachusetts, United States) SyfovreⓇ…
Two Rival Treatments Approved for Geographic Atrophy Under the Spotlight
While doctors cautiously welcome the approval of the two drugs, questions have been raised over safety following reports of rare…
popular posts
latest posts